Healthcare at Home and QED partner on orphan diseases
OrphanReach alliance will see companies provide product lifecycle services
Healthcare at Home and QED Clinical Services have formed a strategic alliance under the OrphanReach banner to support the launch of products for rare and orphan diseases.
Homecare and patient support company Healthcare at Home and QED Clinical Services, a clinical research organisation (CRO), said the alliance would serve a unique market with a unique proposition.
Mike Gordon, CEO for Healthcare at Home, said: "OrphanReach will solve some key problems facing biopharmaceutical companies launching new medicines. It will ensure that pre-launch plans are data rich, evidence based and patient focused. It will ensure that market access is optimised and product launches are as successful as can be."
Services offered by the UK firm’s new OrphanReach alliance will include clinical support and integrated patient management with an ambition to provide "the most integrated clinical development programme and launch plan within rare and orphan conditions".
Healthcare at Home has 15 years’ experience of working in rare and orphan diseases and has supported the launch of many products across Europe, where it has been tasked with services that include running homecare arms in clinical trials.
Meanwhile, global CRO QED was founded in 2002 and has worked on more than 70 rare disease projects.
Its CEO, Thomas Ogorka, said: "We are delighted to be working alongside Healthcare at Home in this strategic alliance. We have a rich track record of optimising clinical development within rare and orphan markets and this alliance enables QED to take the range of services we can offer to a new level but more importantly support clients in a far deeper and more strategic way."
QED is sponsoring the World Orphan Drug Congress 2013, taking place this year on the 14-15 November, at the Starling Geneva Hotel & Convention Center, Geneva, Switzerland. For more information about the event, please visit the website >